Aberdeen Group plc Has $28.06 Million Holdings in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Aberdeen Group plc increased its stake in ANI Pharmaceuticals by 76.1%, acquiring a total of 419,099 shares, valued at approximately $28 million.
• Several analysts have maintained a buy rating on ANI Pharmaceuticals, with price targets ranging between $77.00 and $94.00, and a current consensus price target of $84.75.
• ANI Pharmaceuticals reported earnings of $1.80 per share for the last quarter, exceeding analysts' expectations, with revenue increasing by 53.2% year-over-year, totaling $211.37 million.

Aberdeen Group plc grew its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 76.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 419,099 shares of the specialty pharmaceutical company's stock after acquiring an additional 181,134 shares during the quarter. Aberdeen Group plc owned about 1.92% of ANI Pharmaceuticals worth $28,059,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of ANIP. National Bank of Canada FI purchased a new stake in ANI Pharmaceuticals during the first quarter worth approximately $79,000. GAMMA Investing LLC increased its stake in ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after buying an additional 881 shares during the period. Mesirow Financial Investment Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at approximately $206,000. Rafferty Asset Management LLC acquired a new position in ANI Pharmaceuticals in the fourth quarter worth about $200,000. Finally, Bridgefront Capital LLC acquired a new position in ANI Pharmaceuticals in the fourth quarter worth $204,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Trading Up 0.1%

ANIP stock traded up $0.0760 during midday trading on Friday, reaching $91.2160. The company's stock had a trading volume of 125,863 shares, compared to its average volume of 371,702. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $92.53. The business's 50-day simple moving average is $70.06 and its 200-day simple moving average is $65.69. The stock has a market cap of $1.98 billion, a PE ratio of -118.46 and a beta of 0.61.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The company had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. During the same quarter last year, the firm posted $1.02 earnings per share. ANI Pharmaceuticals's revenue was up 53.2% compared to the same quarter last year. As a group, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $86.97, for a total transaction of $1,739,400.00. Following the transaction, the senior vice president owned 173,226 shares in the company, valued at $15,065,465.22. This trade represents a 10.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Patrick D. Walsh sold 9,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, August 15th. The stock was sold at an average price of $89.05, for a total value of $801,450.00. Following the sale, the director directly owned 70,048 shares of the company's stock, valued at $6,237,774.40. This represents a 11.39% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 301,247 shares of company stock worth $26,264,427 in the last 90 days. Company insiders own 11.10% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $93.00 price target (up previously from $84.00) on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Wall Street Zen raised ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research report on Monday, August 11th. Piper Sandler reissued an "overweight" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Finally, Guggenheim restated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, ANI Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $84.75.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.